{
    "id": "61f939a5882a024a1000004a",
    "question": "Is tivantinib effective for MET-high hepatocellular carcinoma?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To determine if tivantinib is effective for MET-high hepatocellular carcinoma (HCC), let's break down the information step by step.\\n\\n1. Tivantinib is a small molecule inhibitor of the MET receptor tyrosine kinase, which is often overexpressed in various types of cancers, including HCC.\\n2. MET overexpression is associated with poor prognosis and resistance to conventional therapies in HCC.\\n3. Tivantinib has been investigated in clinical trials for its efficacy in treating MET-high HCC.\\n4. The results of the phase II clinical trial (TECANGIO-011) showed that tivantinib significantly improved overall survival (OS) and progression-free survival (PFS) in MET-high HCC patients.\\n5. These findings suggest that tivantinib may be an effective treatment option for MET-high HCC patients.\\n\\nTherefore, based on the available evidence, the answer is: \", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 36.885595083236694
}